Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
PARSIPPANY, N.J., Feb. 11, 2016 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2015 will be released before the market opens on Thursday, February 25, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, February 25, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 93538831.
A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 93538831. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574 [email protected]
